About US
Contact us
-
Dynacure secures orphan drug designation from FDA for DYN101Dynacure has secured orphan drug designation from the US Food and Drug Administration (FDA) for investigational antisense medicine DYN101, which has been designed to modulate the expression of dynami2019/8/7
-
UF researchers focus on new drug candidate Apratoxin S4 to treat vision lossResearchers from the University of Florida (UF) College of Pharmacy have announced a partnership to focus on a new drug candidate Apratoxin S4 as a new method to prevent or treat vision loss. The res2019/8/6
-
NICE approves Keytruda combination therapy for NSCLC through CDFThe UK’s healthcare regulator the National Institute of Health and Care Excellence (NICE) has recommended Merck’s Keytruda (pembrolizumab) combined with two chemotherapy drugs, carboplatin and paclit2019/8/6
-
Takeda whittles away costs—and assets—to keep its debt-cutting promisesTakeda's been cutting costs on one hand and raising cash on the other to pay off its Shire deal debt—and so far, it's on track to hit those goals, executives said this week. The company's cost-saving2019/8/5
-
Pfizer's GSK consumer deal is closed, and generics go next. Will its cash flow recover?The mammoth consumer health deal Pfizer and GlaxoSmithKline struck last December is finally sealed. But things are looking markedly different at Pfizer than they did seven months ago—and that may not2019/8/5
-
After Fresenius deal collapse, Akorn inks $74M settlement with investors over data integrity woesAkorn has had a busy two years in court following a flurry of data integrity woesthat led former merger partner Fresenius to walk away from their deal. Now, it’s putting one issue to rest by settling2019/8/2
-
Takeda whittles away costs—and assets—to keep its debt-cutting promisesTakeda's been cutting costs on one hand and raising cash on the other to pay off its Shire deal debt—and so far, it's on track to hit those goals, executives said this week. The company's cost-saving2019/8/2
-
Pfizer's GSK consumer deal is closed, and generics go next. Will its cash flow recover?The mammoth consumer health deal Pfizer and GlaxoSmithKline struck last December is finally sealed. But things are looking markedly different at Pfizer than they did seven months ago—and that may not2019/8/1
-
Wiping its slate ahead of BMS buy, Celgene to pay $117M in Revlimid antitrust settlementsWith Celgene making the big move under Bristol-Myers Squibb’s umbrella, the drugmaker is looking to clear its books before the merger. Two antitrust settlements totaling more than $100 million could2019/8/1
-
Lilly's Emgality powers ahead with 'best-in-class' CGRP accessEli Lilly’s CGRP migraine prevention drug Emgality is in a heated market share race with Amgen’s Aimovig and Teva’sAjovy, but in the second quarter, it gained some steam. By the end of the perio2019/7/31